It is not credible for institutions to treat company behaviour as external to system performance, particularly in the context of a more assertive US stance on pharmaceutical pricing. Yet what review processes exist are mostly about additional adjustments by stakeholders to the institutional framework. How about changing the framework to recognise realities? …
The importance of humility and understanding the other side of the equation
March 22, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News -
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 - - Latest News -
Patients move to reclaim access agenda ahead of sector negotiations
July 15, 2026 - - Latest News -
An opportunity to become a global destination for paediatric oncology trials
July 15, 2026 - - Latest News